A Target Validation/Phase1 Study of BGB-290 in Combination With Temozolomide in Adolescent and Young Adult IDH1/2 Newly Diagnosed and Recurrent Mutant Gliomas
Volunteers
Health Professionals
What is the purpose of this trial?
This phase I trial studies the side effects and best dose of BGB-290 and temozolomide in treating adolescents and young adults with IDH1/2-mutant grade I-IV glioma that is newly diagnosed or has come back. BGB-290 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving BGB-290 and temozolomide may work better in treating adolescents and young adults with IDH1/2-mutant grade I-IV glioma.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Antonio Omuro, MD
- Claudia Auerbach, APRN
- Farzana Pashankar, MD, MRCP, MBBS
- Juan Vasquez, MD
- Kenneth B. Roberts, MD
- Mary Jane Hogan, MD, MPH, FAAP
- Matthew Dodd, PA-C
- Monika Laurans
- Nicholas Blondin, MD
- Prasanna Ananth, MD, MPH
- Ranjit S. Bindra, MD, PhD
- Rebecca Cheron, APRN
- Rozalyn Levine Rodwin, MD
- Stephanie Massaro, MD, MPH
- Stephanie Prozora, MD
- Vanessa Nevins
- Vidya Puthenpura, MD, MHS, FAAP
- Zachary Corbin, MD, MHS
- Last Updated04/30/2023
- Study HIC#2000025384